A phase 3, multicenter, randomized, evaluation committee-blinded study to assess the efficacy of topical omiganan 1.0 percent gel in preventing local catheter site infections/colonization in patients undergoing central venous catheterization

Trial Profile

A phase 3, multicenter, randomized, evaluation committee-blinded study to assess the efficacy of topical omiganan 1.0 percent gel in preventing local catheter site infections/colonization in patients undergoing central venous catheterization

Completed
Phase of Trial: Phase III

Latest Information Update: 29 Apr 2015

At a glance

  • Drugs Omiganan (Primary) ; Povidone iodine
  • Indications Bacterial infections; Catheter infections
  • Focus Registrational; Therapeutic Use
  • Acronyms CLIRS
  • Sponsors Cadence Pharmaceuticals
  • Most Recent Events

    • 12 Sep 2009 Results reported at ICAAC 2009.
    • 18 Aug 2009 Additional trial location (Germany) identified as reported by ClinicalTrials.gov.
    • 15 Sep 2008 Results are expected in the first quarter of 2009, according to a Cadence Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top